Presbia (LENSF) 10-Q 6 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 05, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	LENS
Entity Registrant Name	PRESBIA PLC
Entity Central Index Key	1,591,096
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		13,355,477

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets
Cash	$ 29,806	$ 138
Accounts receivable	32	25
Inventory	401	378
Prepaid expenses and other current assets	469	122
Total current assets	30,708	663
Property and equipment, net	803	747
Intangible asset	40	46
Other assets	49	886
Total assets	31,600	2,342
Current liabilities
Accounts payable	1,624	1,882
Due to related parties	59	12
Other current liabilities	517	700
Total current liabilities	2,200	2,594
Payable due to the Parent		417
Deferred rent	30	37
Total liabilities	$ 2,230	$ 3,048
Commitments and contingencies (note 10)
Shareholders' equity (deficit)
Ordinary shares	$ 13
Additional paid-in capital	76,601	$ 36,626
Accumulated deficit	(47,298)	(37,386)
Total shareholders' equity (deficit)	29,370	(706)
Total liabilities and shareholders’ equity (deficit)	31,600	2,342
Euro [Member]
Shareholders' equity (deficit)
Ordinary shares	$ 54	$ 54

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical)	Jun. 30, 2015$ / sharesshares	Jun. 30, 2015€ / sharesshares	Dec. 31, 2014$ / sharesshares	Dec. 31, 2014€ / sharesshares
Ordinary shares, par value | (per share)	$ 0.001	€ 1	$ 0.001
Ordinary shares, shares authorized	350,000,000	350,000,000	350,000,000	350,000,000
Ordinary shares, shares issued	13,351,874	13,351,874	0	0
Ordinary shares, shares outstanding	13,351,874	13,351,874	0	0
Euro [Member]
Ordinary shares, par value | € / shares		€ 1		€ 1
Ordinary shares, shares authorized	40,000	40,000	40,000	40,000
Ordinary shares, shares issued	40,000	40,000	40,000	40,000
Ordinary shares, shares outstanding	40,000	40,000	40,000	40,000
United States of America, Dollars [Member]
Ordinary shares, par value | $ / shares	$ 1.35		$ 1.35

Consolidated Statements of Oper

Consolidated Statements of Operation and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenues	$ 42	$ 61	$ 115	$ 87
Cost of goods sold	14	33	61	39
Gross profit	28	28	54	48
Operating expenses:
Research and development	2,502	1,676	4,278	2,407
Sales and marketing	834	394	1,353	643
General and administrative	2,007	4,272	4,326	5,648
Total operating expenses	5,343	6,342	9,957	8,698
Operating loss	(5,315)	(6,314)	(9,903)	(8,650)
Interest expense		584		1,017
Other income		(6)		(6)
Loss before income tax provision	(5,315)	(6,892)	(9,903)	(9,661)
Income tax provision	4	3	9	5
Net loss	(5,319)	(6,895)	(9,912)	(9,666)
Total comprehensive loss	$ (5,319)	$ (6,895)	$ (9,912)	$ (9,666)
Net loss per share-basic and diluted	$ (0.40)	$ (0.75)	$ (0.79)	$ (1.05)
Shares used to compute basic and diluted net loss per share	13,352	9,167	12,562	9,167

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flow from operating activities:
Net loss	$ (9,912)	$ (9,666)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	74	65
Amortization	6	2
Inventory provisions	44	32
Write-off of deferred offering costs		3,359
Share-based compensation (including allocation from Presbia Holdings)	1,403	194
Non-cash interest expense on funding from the Presbia Holdings	1	1,017
Non-cash operating expenses allocated from the Presbia Holdings	182	183
Changes in operating assets and liabilities:
Accounts receivable	(7)	(39)
Inventory	(67)	(111)
Prepaid expenses and other current assets	(347)	27
Other assets	(10)	39
Accounts payable and other current liabilities	884	(238)
Income taxes payable	6	5
Deferred rent	(7)	4
Due to related parties	47	(110)
Net cash used in operating activities	(7,703)	(5,237)
Cash flow from investing activities:
Purchase of property and equipment	(97)	(120)
Net cash used in investing activities	(97)	(120)
Cash flow from financing activities:
Proceeds from issuance of ordinary shares upon initial public offering, net of underwriting costs	38,750
Deferred offering costs	(2,423)	(1,468)
Capitalization of Presbia PLC		54
Funding from the Parent	1,141	6,550
Net cash provided by financing activities	37,468	5,136
Net increase in cash	29,668	(221)
Cash balance at beginning of period	138	584
Cash balance at end of period	29,806	363
Supplemental disclosure of cash flow information:
Cash paid for income taxes	3
Supplemental disclosures of non-cash investing and financing activities:
Purchase of property and equipment included in accounts payable	33
Deferred offering costs included in accounts payable and other current liabilities		1,246
Deferred offering costs included in Due to Presbia Holdings		650
Allocated operating expenses funded by the Presbia Holdings	182	$ 183
Capitalization of amounts due to Presbia Holdings persuant to the 2015 Debt Conversion	$ 1,559

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	(1) Basis of Presentation Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a direct subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia USA, Inc., and OPL, LLC. Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation. 2013 Restructuring and Formation of Presbia PLC . Presbia PLC, an Irish public limited company, was formed on February 6, 2014 through the issuance of 40,000 shares for 40,000 Euros (approximately $54,000) for the purpose of consummating an initial public offering of its ordinary shares. Presbia PLC’s ultimate controlling shareholder, Presbia Holdings (the “Parent”), was organized in the Cayman Islands in 2007 as an exempted company with limited liability. On October 21, 2013, the Parent completed a restructuring (the “2013 Restructuring”) which involved the formation on September 13, 2013 of an interim holding company, Presbia Ireland, Limited, and the contribution by the Parent of 100% of its direct and indirect ownership interests in its business, assets and subsidiaries to Presbia Ireland, Limited. At the time of the 2013 Restructuring, Presbia Ireland, Limited was wholly-owned by Presbia Holdings and certain intercompany debt was owed to Presbia Holdings by certain of its other subsidiaries. As part of the 2013 Restructuring, approximately $12.2 million of such outstanding intercompany debt owed to Presbia Holdings was converted to equity of such subsidiaries. 2014 Debt Conversion. On November 30, 2014, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by certain subsidiaries of Presbia Ireland, Limited at that time to equity (“2014 Debt Conversion”). In the 2014 Debt Conversion, approximately $23.5 million of outstanding intercompany debt owed to Presbia Holdings was converted to equity of Presbia Ireland, Limited. 2015 Debt Conversion. On January 14, 2015, the Parent converted all the remaining indebtedness owed to the Parent by a subsidiary of Presbia Ireland, Limited at that time to equity (the “2015 Debt Conversion”) in the amount of approximately $1.6 million. See Note 4 for additional discussion. 2015 Capital Contribution. On January 14, 2015, the Parent contributed all the share capital in issue in Presbia Ireland, Limited to Presbia PLC (the “2015 Capital Contribution”) in exchange for 9,166,667 ordinary shares of Presbia PLC. See Note 4 for additional discussion. Initial Public Offering. On February 3, 2015, Presbia PLC completed its initial public offering (“IPO”) of 4,166,667 of its ordinary shares at a price to the public of $10.00 per ordinary share and commenced trading on The NASDAQ Global Market under the symbol LENS. The Parent acquired 500,000 ordinary shares in the public offering. The net proceeds from the IPO consisted of aggregate gross proceeds of approximately $41.7 million, less underwriting discounts and commissions of approximately $2.9 million and other issuance costs of approximately $2.0 million, resulting in net proceeds of approximately $36.8 million. Liquidation of Presbia Holdings. On May 13, 2015, the board of directors and the ordinary shareholders of Presbia Holdings approved a voluntary liquidation of Presbia Holdings and the distribution of its assets consisting primarily of 9,666,667 shares of Presbia PLC shares, of which 500,000 shares were acquired during the initial public offering and 9,166,667 were acquired pursuant to the 2015 Capital Contribution, to its ordinary shareholders. On May 13, 2015, the shareholders also approved a plan that would immediately fully vest all outstanding options and restricted share awards and, in the case of the options, accelerate the expiration date of all such options to June 15, 2015. See Notes 6 and 11 for further discussion. Basis of Presentation. The accompanying unaudited consolidated financial statements as of June 30, 2015 and for the three months and six months ended June 30, 2015 and 2014 have been prepared in accordance with the requirements of Form 10-Q and Article 10 of the Securities and Exchange Commission Regulation S-X and therefore do not include all information and notes which would be presented were such consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Amounts related to disclosures of December 31, 2014 balances within these interim consolidated financial statements were derived from the aforementioned Form 10-K. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified. Liquidity The Company has incurred significant operating losses since inception and had relied on funding from the Parent to fund operations prior to its IPO on February 3, 2015. At June 30, 2015, the Company has an accumulated deficit of $47.3 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its product and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Management expects that existing cash as of June 30, 2015 will be sufficient to fund the Company’s operations for at least twelve months from the balance sheet date.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies Revenue Recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. As of June 30, 2015, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. Clinical Trials During 2014, the Company received approval from the United States Food and Drug Administration (“FDA”) to commence a staged-enrollment pivotal FDA clinical trial of its microlens involving the implantation of presbyopic patients. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies and third parties to monitor the investigational sites and perform data collection activities and surgeon costs, as well as patient fees in connection with the surgical procedures and follow-up visits. In February 2015, the Company received approval from the FDA to commence second stage enrollment in this trial. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense. Deferred Offering Costs During the three and six months ended June 30, 2015, the Company incurred approximately $1.2 million, respectively, related to its IPO which was completed on February 3, 2015. Upon completion of the IPO, the Company netted approximately $2.0 million in offering costs, including approximately $0.8 million recorded as other assets on the balance sheet as of December 31, 2014, against the gross proceeds in shareholders’ deficit. During the three and six months ended June 30, 2014, the Company wrote-off approximately $3.4 million in deferred offering costs due to delays beyond 90 days in the launch of its initial public offering. Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. Amounts payable to related parties, which has no fixed maturity or expiration date, do not have readily determinable fair values. Recent Accounting Standards In January 2015, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2015-01 which simplifies income statement presentation by eliminating the need to determine whether to classify an item as an extraordinary item. This ASU applies to all entities and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, but adoption must occur at the beginning of a fiscal year. An entity can elect to apply the guidance prospectively or retrospectively. The Company is currently evaluating the potential impact that the adoption of this guidance will have on its consolidated financial statements. In May 2014, FASB issued an Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers: Topic 606 Revenue Recognition, Revenue Recognition—Construction-Type and Production-Type Contracts. Property, Plant, and Equipment, Intangibles—Goodwill and Other) The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. For public companies, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. The Company is evaluating the potential impact of adoption of this ASU on its consolidated financial statements.

Composition of Certain Financia

Composition of Certain Financial Statement Captions	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Composition of Certain Financial Statement Captions	(3) Composition of Certain Financial Statement Captions Inventory is summarized as follows: June 30, 2015 December 31, 2014 Lenses 323 $ 371 Accessories 78 7 Total $ 401 $ 378 During the three and six months ended June 30, 2015, the Company incurred approximately $70,000 to build inserter inventory, respectively, consisting of approximately $35,000 of production inventory parts in preparation for internal production of a disposable inserter and approximately $35,000 for purchases of other inserters. Property and equipment is summarized as follows: June 30, 2015 December 31, 2014 Office equipment and computers $ 65 $ 51 Leasehold improvements 142 132 Production equipment and facilities 714 682 Software 23 7 Construction in process 57 0 Furniture and vehicles 156 155 1,157 1,027 Less: accumulated depreciation (354 ) (280 ) Property & Equipment, net $ 803 $ 747 Other assets are summarized as follows: June 30, 2015 December 31, 2014 Prepaid rent and other $ 49 $ 47 Deferred costs related to IPO — 839 Total $ 49 $ 886 Other current liabilities are summarized as follows: June 30, 2015 December 31, 2014 Costs related to the IPO $ — $ 327 Accrued professional fees 95 20 Accrued payroll & vacation 44 114 Other accrued liabilities 378 239 Total $ 517 $ 700

Shareholders' Deficit

Shareholders' Deficit	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Shareholders' Deficit	(4) Shareholders’ Deficit Common Ordinary Shares and Deferred Ordinary Shares As of June 30, 2015, the share capital of Presbia PLC was $400,000 and €40,000, divided into: 350,000,000 ordinary shares of $0.001 each (the “Ordinary Shares”), 13,351,874 of which were outstanding as of June 30, 2015; 50,000,000 preferred shares of $0.001 (the “Preferred Shares”) each, all of which are authorized but unissued; and 40,000 deferred ordinary shares of €1.00 each (the “Deferred Ordinary Shares”), all of which are issued and outstanding as of June 30, 2015. The aggregate 9,166,667 ordinary shares of Presbia PLC have been reflected as issued and outstanding as of the earliest date of the periods presented for purposes of computation of comparable basic and diluted net loss per share. The rights and restrictions attaching to the Ordinary Shares are as follows: the right to attend and speak at any general meeting of the Company and to exercise one vote per Ordinary Share held at any general meeting of the Company; the right to participate pro rata in all dividends declared by the Company; and the right, in the event of the Company’s winding up, to participate pro rata in the total assets of the Company. The Deferred Ordinary Shares were initially issued as 40,000 ordinary shares of one Euro each on February 6, 2014 in connection with the formation of Presbia PLC. On January 14, 2015, the Company amended its memorandum and articles of association, resulting in the re-designation of such shares as deferred ordinary shares. the rights and restrictions attaching to the Deferred Ordinary Shares are as follows: Income: The holder of a Deferred Ordinary Share shall not be entitled to receive any dividend or distribution declared, made or paid or any return of capital (save as provided below) and a Deferred Ordinary Share shall not entitle its holder to any further or other right of participation in the assets of the Company; Capital: On a winding up of, or other return of capital (other than on a redemption of any class of shares in the capital of the Company) by the Company, the holders of Deferred Ordinary Shares shall be entitled to participate in such return of capital or winding up of the Company, such entitlement to be limited to the repayment of the amount paid up or credited as paid up on such Deferred Ordinary Shares and shall be paid only after the holders of Ordinary Shares shall have received payment in respect of such amount as is paid up or credited as paid up on those Ordinary Shares held by them at that time, plus the payment in cash of $5,000,000 on each such Ordinary Share. Acquisition of Deferred Ordinary Shares: The Company as agent for the holders of Deferred Ordinary Shares shall have the irrevocable authority to authorize and instruct the Company’s secretary (or any other person appointed for the purpose by the Company’s board of directors) to acquire, or to accept the surrender of, the Deferred Ordinary Shares for no consideration and to execute on behalf of such holders such documents as are necessary in connection with such acquisition or surrender, and pending such acquisition or surrender to retain the certificates, to the extent issued, for such Deferred Ordinary Shares. Voting: The holders of Deferred Ordinary Shares shall not be entitled to receive notice of, nor attend, speak or vote at, any general meeting. The rights attaching to the Preferred Shares will be determined by the Company’s board of directors. The directors are authorized to issue all or any of the authorized but unissued Preferred Shares from time to time in one or more classes or series, and to fix for each such class or series such voting power, full or limited, or no voting power, and such designations, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board providing for the issuance of such class or series, including, without limitation, the authority to provide that any such class or series may be: redeemable at the option of the Company, or the holders, or both, with the manner of the redemption to be set by the Company’s board of directors, and redeemable at such time or times, including upon a fixed date, and at such price or prices, as shall be determined by the Board; entitled to receive dividends (which may be cumulative or non-cumulative) at such rates, on such conditions and at such times, and payable in preference to, or in such relation to, the dividends payable on any other class or classes of shares or any other series all as shall be determined by the Board; entitled to such rights upon the dissolution of, or upon any distribution of the assets of, the Company, as shall be determined by the Board; or convertible into, or exchangeable for, shares of any other class or classes of shares, or of any other series of the same or any other class or classes of shares, of the Company, at such price or prices or at such rates of exchange and with such adjustments as the Company’s board of directors determines. Additional Paid-in Capital On January 14, 2015, the Parent entered into a Debt Conversion Agreement pursuant to which all outstanding amounts owed to the Parent under the Interest Rate Agreement governing such debt at that time were contributed to paid-in capital of certain of the Parent’s subsidiaries. Additional paid-in capital was $76.6 million as of June 30, 2015, compared to $36.6 million as of December 31, 2014. The change consists of a contribution of approximately $1.6 million pursuant to the Debt Conversion Agreement, share-based compensation of $1.4 million, payments of $0.2 million of bonuses paid by Presbia Holdings on behalf of the Company and net proceeds of $36.8 million from the Company’s IPO.

Loss per Share

Loss per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Loss per Share	(5) Loss per Share Unvested share-based payment awards that contain non-forfeitable rights to dividends are participating securities that should be included in computing loss per share using the two-class method. The Company’s nonvested restricted shares qualify as participating securities. Basic net loss per ordinary share is calculated by dividing net loss allocated to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded. Basic and diluted loss per share were calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Basic and diluted net loss per share Net loss $ (5,319 ) $ (6,895 ) $ (9,912 ) $ (9,666 ) Net loss allocated to common shareholders $ (5,319 ) $ (6,895 ) $ (9,912 ) $ (9,666 ) Weighted average shares outstanding - Basic and diluted 13,352 9,167 12,562 9,167 Basic and diluted net loss per share $ (0.40 ) $ (0.75 ) $ (0.79 ) $ (1.05 ) The aggregate 9,166,667 ordinary shares of the Company as discussed in Note 4 have been reflected as issued and outstanding as June 30, 2014 for purposes of computation of basic and diluted net loss per share. Antidilutive securities, which consist of options and restricted shares that are not included in the diluted net loss per share calculation, consisted of an aggregate of approximately 1,029,069 and 840,202 weighted average shares for the three and six months ended June 30, 2015, respectively.

Share Based Awards

Share Based Awards	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Based Awards	(6) Share Based Awards Equity Issued by Parent Prior to January 14, 2015 and the Company’s IPO, the Parent granted options to purchase its ordinary shares and granted awards of restricted ordinary shares, to both employees and non-employees of the Company and share-based compensation related to such awards is recognized as expense in the accompanying consolidated financial statements. Information regarding prior period awards is available in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014. No new options or restricted shares were granted by the Parent during the six month period ended June 30, 2015. On May 13, 2015, the shareholders of the Parent approved a plan in which all options and unvested restricted shares outstanding as of that date were to become fully vested and, in the case of the options, the expiration date of the options were accelerated to June 15, 2015. On May 13, 2015, approximately 4.7 million options were outstanding and 1.4 million restricted shares were unvested. During the prescribed exercise period, 3,785,000 options were exercised at an exercise price of $0.08 and 956,250 options were cancelled or forfeited at an average exercise price of $0.24 per option. Stock-based compensation expense of approximately $21,000 was recorded in the three month period ended June 30, 2015 in connection with the acceleration of the vesting periods for 665,000 unvested options. The following table sets forth the Parent’s option activity for the six months ended June 30, 2015: Weighted Average Number Of Exercise Aggregate Parent's PricePer Intrinsic Parent Shares Share Value Balance, December 31, 2014 4,835,000 $ 0.11 Granted — $ — Exercised (3,860,000 ) $ 0.08 $ 656 Forfeited/cancelled (975,000 ) $ 0.24 Balance, June 30, 2015 — $ — Restricted Shares No restricted shares were granted by the Parent during the six months ended June 30, 2015. As of May 13, 2015, there were 1,400,000 unvested restricted shares of the Parent with a weighted average grant date fair value of $0.30 per share. Pursuant to the plan to immediately accelerate the vesting periods of the restricted shares adopted on May 13, 2015, approximately $104,000, using a fair value of $0.26 per ordinary share, was recognized as stock-based compensation in the three months ended June 30, 2015 in connection with 400,000 unvested shares. The other 1.0 million unvested restricted shares had been fully expensed at the time of grant in 2013. Unrecognized Share-based Compensation As of June 30, 2015, there was no unrecognized stock-based compensation expense related to the awards issued by the Parent. Equity Issued by Presbia PLC Presbia Incentive Plan On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted share units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including annual and long-term cash incentive awards. A total of 1,800,000 ordinary shares are authorized for issuance under the Presbia Incentive Plan of which approximately 702,000 were available on June 30, 2015 for future grants and awards. The exercise price of each option award shall be determined by the Board of Directors (or a committee thereof) at the date of grant in accordance with the terms of the 2005 Plan, and under the 2005 Plan awards generally vest 20% annually over a five-year period and expire no later than 10 years from the grant date. The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors. Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company. The following table shows share-based compensation expense included in the consolidated statements of operations and comprehensive income for the three and six months ended June 30, 2015 and 2014. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Research and development $ 81 $ 52 $ 107 $ 135 General and administrative 424 28 1,220 49 Sales and marketing 46 5 76 10 Total $ 551 $ 85 $ 1,403 $ 194 Options The following table sets forth the Company’s option activity for the six months ended June 30, 2015: Weighted Average Exercise Number Of Price Per Presbia PLC Shares Share Balance, December 31, 2014 — $ — Granted 1,089,000 $ 9.80 Forfeited/cancelled (9,750 ) $ 8.63 Balance, June 30, 2015 1,079,250 $ 9.81 Vested and expected to vest, June 30, 2015 972,000 $ 9.80 Exercisable, June 30, 2015 92,000 $ 9.97 Employee Options The Company utilizes the Black-Scholes valuation model for estimating the fair value of share-based compensation with the following assumptions. The Company estimated expected life utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of the "plain-vanilla" options as defined by the Securities Exchange Commission. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award. The following table presents the grant date assumptions used in the Black-Scholes model for determining the fair value of 1,022,500 employee options issued during the six months ended June 30, 2015: Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Expected life 6.5 years 5.5-6.5 years Expected volatility 84.5% 76.8% - 84.5% Expected dividends 0% 0% Risk-free rate 1.8% 1.3% - 1.8% The weighted-average grant date fair value of the employee options granted during the six months ended June 30, 2015 was $6.98 per share. For those options granted to employees, stock-based compensation expense is based upon the fair value of the option as of the grant-date and attributed to future reporting periods on a straight-line basis over the vesting period, or the requisite service period. A 5% forfeiture rate assumption was applied, which reduces the amount of expense recognized each period anticipating that a portion of all options granted will, more likely than not, be cancelled prior to the dates of its vesting periods. The forfeiture rate is subject to review and may be adjusted based upon experience. Non-Employee Options During the six month ended June 30, 2015, 66,500 options were granted to non-employee consultants and medical advisors in which the following assumptions were used in the Black-Scholes valuation model to determine the option fair values: Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Expected life 9.9 years 9.9 years Expected volatility 78.8% 78.80% Expected dividends 0% 0% Risk-free rate 2.4% 1.9% - 2.4% In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared. Because the performance criteria of these grants is based solely upon a requisite service period, but are subject to forfeiture if the service conditions are not met, stock-based compensation expense is determined by a straight-line attribution of the remeasured expense (mark-to-market) over the requisite service subject to a forfeiture rate of 5%. Restricted Shares On March 16, 2015, the Company’s board of directors approved grants of 9,270 restricted ordinary shares of the Company each to Robert J. Cresci and to Mark Blumenkranz, both of whom are board members. The aggregate 18,540 shares vest in five equal, annual installments commencing one year after the date of grant. The weighted-average grant date fair value for the restricted shares was estimated using the market price of the ordinary shares on the date of grant ($8.63 per share on March 16, 2015). As of June 30, 2015, there were 18,540 restricted shares of the Company outstanding with a weighted average grant date fair value of $8.63 per share. The Company recorded compensation expense related to restricted shares of approximately $8,000 and $9,300 for the three months and six months ended June 30, 2015, respectively. The following table sets forth the Company’s restricted share activity for the six months ended June 30, 2015: Weighted Average Number Of Fair Value Presbia PLC Shares Per Share Balance, December 31, 2014 - $ - Granted 18,540 $ 8.63 Balance, June 30, 2015 18,540 $ 8.63 Vested and expected to vest, June 30, 2015 18,540 $ 8.63 Exercisable, June 30, 2015 - $ - Unrecognized Share-based Compensation As of June 30, 2015, there was $5.1 million and $0.4 million of unrecognized compensation expense related to employee and non-employee options of the Company, respectively, which is expected to be recognized by the Company over the weighted average vesting period of 4.0 years. Unrecognized compensation expense related to restricted shares was $151,000 as of June 30, 2015 and is expected to be recognized over the weighted average vesting period of 4.7 years.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	(7) Related Party Transactions The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets: June 30, 2015 December 31, 2014 Payable to related parties—current: Management services provided by related parties $ 59 $ 12 Total $ 59 $ 12 Payable due to the Parent—noncurrent: Principal amounts due to the Parent $ — $ 417 Accrued interest due to the Parent — — Total $ — $ 417

Concentration of Credit Risk

Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2015
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	(8) Concentration of Credit Risk The Company had cash of $29.8 million and $138,000 as of June 30, 2015 and December 31, 2014, respectively, which consists of checking account deposits.

Operating Segments and Geograph

Operating Segments and Geographic Information	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Operating Segments and Geographic Information	(9) Operating Segments and Geographic Information The Company has one reportable segment that is evaluated regularly by its chief decision making group in deciding how to allocate resources and in assessing performance. The following tables set forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area: Three Months Ended June 30, Six Months Ended June 30, REVENUES 2015 2014 2015 2014 Ireland $ 25 $ 60 $ 60 $ 81 Korea — — 36 — Japan — — — 5 Netherlands 11 — 11 — Australia 1 — 1 — Canada 5 1 7 1 Total $ 42 $ 61 $ 115 $ 87 LONG-LIVED ASSETS June 30, 2015 December 31, 2014 U.S. $ 771 $ 716 Foreign 32 31 Total $ 803 $ 747

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(10) Commitments and Contingencies From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial operations.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	(11) Subsequent Event On August 3, 2015, Presbia Holdings, as part of the liquidation plan approved on May 13, 2015 by its shareholders, completed the distribution to its shareholders of 9,666,667 ordinary shares of Presbia PLC and 39,994 of deferred ordinary shares, representing all of its holdings in Presbia PLC.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a direct subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia USA, Inc., and OPL, LLC. Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation.
Basis of Presentation	Basis of Presentation. The accompanying unaudited consolidated financial statements as of June 30, 2015 and for the three months and six months ended June 30, 2015 and 2014 have been prepared in accordance with the requirements of Form 10-Q and Article 10 of the Securities and Exchange Commission Regulation S-X and therefore do not include all information and notes which would be presented were such consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Amounts related to disclosures of December 31, 2014 balances within these interim consolidated financial statements were derived from the aforementioned Form 10-K. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified.
Liquidity	Liquidity The Company has incurred significant operating losses since inception and had relied on funding from the Parent to fund operations prior to its IPO on February 3, 2015. At June 30, 2015, the Company has an accumulated deficit of $47.3 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its product and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Management expects that existing cash as of June 30, 2015 will be sufficient to fund the Company’s operations for at least twelve months from the balance sheet date.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. As of June 30, 2015, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers.
Clinical Trials	Clinical Trials During 2014, the Company received approval from the United States Food and Drug Administration (“FDA”) to commence a staged-enrollment pivotal FDA clinical trial of its microlens involving the implantation of presbyopic patients. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies and third parties to monitor the investigational sites and perform data collection activities and surgeon costs, as well as patient fees in connection with the surgical procedures and follow-up visits. In February 2015, the Company received approval from the FDA to commence second stage enrollment in this trial. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense.
Deferred Offering Costs	Deferred Offering Costs During the three and six months ended June 30, 2015, the Company incurred approximately $1.2 million, respectively, related to its IPO which was completed on February 3, 2015. Upon completion of the IPO, the Company netted approximately $2.0 million in offering costs, including approximately $0.8 million recorded as other assets on the balance sheet as of December 31, 2014, against the gross proceeds in shareholders’ deficit. During the three and six months ended June 30, 2014, the Company wrote-off approximately $3.4 million in deferred offering costs due to delays beyond 90 days in the launch of its initial public offering.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. Amounts payable to related parties, which has no fixed maturity or expiration date, do not have readily determinable fair values.
Recent Accounting Standards	Recent Accounting Standards In January 2015, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2015-01 which simplifies income statement presentation by eliminating the need to determine whether to classify an item as an extraordinary item. This ASU applies to all entities and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, but adoption must occur at the beginning of a fiscal year. An entity can elect to apply the guidance prospectively or retrospectively. The Company is currently evaluating the potential impact that the adoption of this guidance will have on its consolidated financial statements. In May 2014, FASB issued an Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers: Topic 606 Revenue Recognition, Revenue Recognition—Construction-Type and Production-Type Contracts. Property, Plant, and Equipment, Intangibles—Goodwill and Other) The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. For public companies, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. The Company is evaluating the potential impact of adoption of this ASU on its consolidated financial statements.

Composition of Certain Financ18

Composition of Certain Financial Statement Captions (Tables)	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Inventory	Inventory is summarized as follows: June 30, 2015 December 31, 2014 Lenses 323 $ 371 Accessories 78 7 Total $ 401 $ 378
Summary of Property and Equipment	Property and equipment is summarized as follows: June 30, 2015 December 31, 2014 Office equipment and computers $ 65 $ 51 Leasehold improvements 142 132 Production equipment and facilities 714 682 Software 23 7 Construction in process 57 0 Furniture and vehicles 156 155 1,157 1,027 Less: accumulated depreciation (354 ) (280 ) Property & Equipment, net $ 803 $ 747
Summary of Other Assets	Other assets are summarized as follows: June 30, 2015 December 31, 2014 Prepaid rent and other $ 49 $ 47 Deferred costs related to IPO — 839 Total $ 49 $ 886
Summary of Other Current Liabilities	Other current liabilities are summarized as follows: June 30, 2015 December 31, 2014 Costs related to the IPO $ — $ 327 Accrued professional fees 95 20 Accrued payroll & vacation 44 114 Other accrued liabilities 378 239 Total $ 517 $ 700

Loss per Share (Tables)

Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of Calculation of Basic and Diluted Loss per Share	Basic and diluted loss per share were calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Basic and diluted net loss per share Net loss $ (5,319 ) $ (6,895 ) $ (9,912 ) $ (9,666 ) Net loss allocated to common shareholders $ (5,319 ) $ (6,895 ) $ (9,912 ) $ (9,666 ) Weighted average shares outstanding - Basic and diluted 13,352 9,167 12,562 9,167 Basic and diluted net loss per share $ (0.40 ) $ (0.75 ) $ (0.79 ) $ (1.05 )

Share Based Awards (Tables)

Share Based Awards (Tables)	6 Months Ended
	Jun. 30, 2015
Schedule of Option Activity	The following table sets forth the Company’s option activity for the six months ended June 30, 2015: Weighted Average Exercise Number Of Price Per Presbia PLC Shares Share Balance, December 31, 2014 — $ — Granted 1,089,000 $ 9.80 Forfeited/cancelled (9,750 ) $ 8.63 Balance, June 30, 2015 1,079,250 $ 9.81 Vested and expected to vest, June 30, 2015 972,000 $ 9.80 Exercisable, June 30, 2015 92,000 $ 9.97
Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Income	The following table shows share-based compensation expense included in the consolidated statements of operations and comprehensive income for the three and six months ended June 30, 2015 and 2014. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Research and development $ 81 $ 52 $ 107 $ 135 General and administrative 424 28 1,220 49 Sales and marketing 46 5 76 10 Total $ 551 $ 85 $ 1,403 $ 194
Schedule of Restricted Shares Activity	The following table sets forth the Company’s restricted share activity for the six months ended June 30, 2015: Weighted Average Number Of Fair Value Presbia PLC Shares Per Share Balance, December 31, 2014 - $ - Granted 18,540 $ 8.63 Balance, June 30, 2015 18,540 $ 8.63 Vested and expected to vest, June 30, 2015 18,540 $ 8.63 Exercisable, June 30, 2015 - $ -
Employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	The following table presents the grant date assumptions used in the Black-Scholes model for determining the fair value of 1,022,500 employee options issued during the six months ended June 30, 2015: Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Expected life 6.5 years 5.5-6.5 years Expected volatility 84.5% 76.8% - 84.5% Expected dividends 0% 0% Risk-free rate 1.8% 1.3% - 1.8%
Non-employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	Non-Employee Options During the six month ended June 30, 2015, 66,500 options were granted to non-employee consultants and medical advisors in which the following assumptions were used in the Black-Scholes valuation model to determine the option fair values: Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Expected life 9.9 years 9.9 years Expected volatility 78.8% 78.80% Expected dividends 0% 0% Risk-free rate 2.4% 1.9% - 2.4%
Presbia Holdings [Member]
Schedule of Option Activity	The following table sets forth the Parent’s option activity for the six months ended June 30, 2015: Weighted Average Number Of Exercise Aggregate Parent's PricePer Intrinsic Parent Shares Share Value Balance, December 31, 2014 4,835,000 $ 0.11 Granted — $ — Exercised (3,860,000 ) $ 0.08 $ 656 Forfeited/cancelled (975,000 ) $ 0.24 Balance, June 30, 2015 — $ —

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Schedule of Amounts Due to Related Parties	The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets: June 30, 2015 December 31, 2014 Payable to related parties—current: Management services provided by related parties $ 59 $ 12 Total $ 59 $ 12 Payable due to the Parent—noncurrent: Principal amounts due to the Parent $ — $ 417 Accrued interest due to the Parent — — Total $ — $ 417

Operating Segments and Geogra22

Operating Segments and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of Revenues Generated from External Customers and Long-lived Assets by Area	The following tables set forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area: Three Months Ended June 30, Six Months Ended June 30, REVENUES 2015 2014 2015 2014 Ireland $ 25 $ 60 $ 60 $ 81 Korea — — 36 — Japan — — — 5 Netherlands 11 — 11 — Australia 1 — 1 — Canada 5 1 7 1 Total $ 42 $ 61 $ 115 $ 87 LONG-LIVED ASSETS June 30, 2015 December 31, 2014 U.S. $ 771 $ 716 Foreign 32 31 Total $ 803 $ 747

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail)	May. 13, 2015shares	Feb. 03, 2015USD ($)$ / sharesshares	Jan. 14, 2015USD ($)shares	Nov. 30, 2014USD ($)	Feb. 06, 2014USD ($)shares	Feb. 06, 2014EUR (€)shares	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)shares	Dec. 31, 2014USD ($)
Basis Of Presentation [Line Items]
Date of incorporation							Feb. 6, 2014
Capitalization of amounts due to Presbia Holdings pursuant to Debt Conversion			$ 1,600,000	$ 23,500,000			$ 1,559,000
Gross proceeds from issuance of stock							38,750,000
Other issuance costs							2,423,000	$ 1,468,000
Accumulated deficit							(47,298,000)		$ (37,386,000)
2015 Capital Contribution [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares								9,166,667
IPO [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares		4,166,667
Ordinary shares, price per share | $ / shares		$ 10
Gross proceeds from issuance of stock		$ 41,700,000
Underwriting discounts and commission costs		2,900,000
Other issuance costs		2,000,000					2,000,000
Net proceeds from issuance of stock		$ 36,800,000					$ 36,800,000
IPO [Member] | 2015 Capital Contribution [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares			9,166,667
Presbia Holdings [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares	9,666,667				40,000	40,000
Number of ordinary shares, value					$ 54,000	€ 40,000
Percentage of ownership interests					100.00%	100.00%
Capitalization of amounts due to Presbia Holdings pursuant to Debt Conversion					$ 12,200,000
Presbia Holdings [Member] | 2015 Capital Contribution [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares	9,166,667
Presbia Holdings [Member] | IPO [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares	500,000	500,000

Summary of Significant Accoun24

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	Feb. 03, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Subsidiary Sale Of Stock [Line Items]
Write-off of deferred offering costs				$ 3,359
Payment of offering costs			$ 2,423	1,468
Other assets			49		$ 886
IPO [Member]
Subsidiary Sale Of Stock [Line Items]
Deferred offering costs			1,200
Write-off of deferred offering costs		$ 3,359		$ 3,359
Payment of offering costs	$ 2,000		$ 2,000
Other assets					$ 800
Deferred offering cost due to delay				90 days

Composition of Certain Financ25

Composition of Certain Financial Statement Captions - Summary of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Total	$ 401	$ 378
Lenses [Member]
Inventory [Line Items]
Total	323	371
Accessories [Member]
Inventory [Line Items]
Total	$ 78	$ 7

Composition of Certain Financ26

Composition of Certain Financial Statement Captions - Additional Information (Detail)	Jun. 30, 2015USD ($)
Inserters [Member]
Inventory [Line Items]
Inventory finished goods	$ 70,000
Inventory internal process	35,000
Other Inserters [Member]
Inventory [Line Items]
Purchase of other inserters	$ 35,000

Composition of Certain Financ27

Composition of Certain Financial Statement Captions - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,157	$ 1,027
Less: accumulated depreciation	(354)	(280)
Property & Equipment, net	803	747
Office equipment and computers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	65	51
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	142	132
Production equipment and facilities [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	714	682
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	23	7
Construction in process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	57	0
Furniture and vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 156	$ 155

Composition of Certain Financ28

Composition of Certain Financial Statement Captions - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Other Assets Noncurrent Disclosure [Line Items]
Prepaid rent and other	$ 49	$ 47
Total	$ 49	886
IPO [Member]
Other Assets Noncurrent Disclosure [Line Items]
Deferred costs related to IPO		839
Total		$ 800

Composition of Certain Financ29

Composition of Certain Financial Statement Captions - Summary of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Other Liabilities Current [Abstract]
Costs related to the IPO		$ 327
Accrued professional fees	$ 95	20
Accrued payroll & vacation	44	114
Other accrued liabilities	378	239
Total	$ 517	$ 700

Shareholders' Deficit - Additio

Shareholders' Deficit - Additional Information (Detail)	Jun. 30, 2015USD ($)$ / sharesshares	Feb. 03, 2015USD ($)	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014shares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014shares	Jun. 30, 2015EUR (€)€ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2014€ / shares	Feb. 06, 2014shares
Class of Stock [Line Items]
Share capital	$ 400,000		$ 400,000		$ 400,000		€ 40,000
Shares authorized	350,000,000		350,000,000		350,000,000		350,000,000	350,000,000
Ordinary shares, par value | (per share)	$ 0.001		$ 0.001		$ 0.001		€ 1	$ 0.001
Ordinary shares, shares outstanding	13,351,874		13,351,874		13,351,874		13,351,874	0
Preferred shares, authorized	50,000,000		50,000,000		50,000,000		50,000,000
Preferred shares, par value | $ / shares	$ 0.001		$ 0.001		$ 0.001
Weighted average shares outstanding - basic and diluted			13,352,000	9,167,000	12,562,000	9,167,000
Payment for ordinary share | $					$ 5,000,000
Additional paid-in capital | $	$ 76,601,000		$ 76,601,000		76,601,000			$ 36,626,000
Capital contribution related to debt conversion | $					1,600,000
Capital contribution related to share-based compensation | $					1,400,000
Payment of bonus | $					200,000
IPO [Member]
Class of Stock [Line Items]
Net proceeds from issuance of stock | $		$ 36,800,000			$ 36,800,000
Euro [Member]
Class of Stock [Line Items]
Shares authorized	40,000		40,000		40,000		40,000	40,000
Ordinary shares, par value | € / shares							€ 1		€ 1
Ordinary shares, shares outstanding	40,000		40,000		40,000		40,000	40,000
Deferred ordinary shares issued										40,000
2015 Capital Contribution [Member]
Class of Stock [Line Items]
Weighted average shares outstanding - basic and diluted	9,166,667					9,166,667

Loss per Share - Schedule of Ca

Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Basic and diluted net loss per share
Net loss	$ (5,319)	$ (6,895)	$ (9,912)	$ (9,666)
Net loss allocated to common shareholders	$ (5,319)	$ (6,895)	$ (9,912)	$ (9,666)
Weighted average shares outstanding - basic and diluted	13,352	9,167	12,562	9,167
Basic and diluted net loss per share	$ (0.40)	$ (0.75)	$ (0.79)	$ (1.05)

Loss per Share - Additional Inf

Loss per Share - Additional Information (Detail) - shares	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Weighted average shares outstanding - basic and diluted		13,352,000	9,167,000	12,562,000	9,167,000
Antidilutive securities, not included in diluted net loss per calculation		1,029,069		840,202
2015 Capital Contribution [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Ordinary shares, shares issued					9,166,667
Weighted average shares outstanding - basic and diluted	9,166,667				9,166,667

Share Based Awards - Additional

Share Based Awards - Additional Information (Detail) - USD ($)	May. 13, 2015	Mar. 16, 2015	Jan. 14, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted						1,089,000
Options outstanding				1,079,250		1,079,250
Options cancelled						9,750
Options forfeited/cancelled, weighted average exercise price per share						$ 8.63
Share-based compensation expense				$ 551,000	$ 85,000	$ 1,403,000	$ 194,000
Restricted shares granted		9,270
Non-employee consultants and medical advisors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted						66,500
Presbia Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Awards vesting period			5 years
Ordinary shares authorized for issuance			1,800,000
Ordinary shares available for future grants and awards				702,000		702,000
Award expiration period			10 years
Award expiration date						Jan. 14, 2025
Presbia Incentive Plan [Member] | Over five year period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual			20.00%
Restricted shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted						18,540
Restricted shares outstanding				18,540		18,540
Share-based compensation expense				$ 8,000		$ 9,300
Weighted average grant date fair value				$ 8.63		$ 8.63
Awards vesting period		5 years
Weighted average grant date fair value, granted		$ 8.63				$ 8.63
Unrecognized compensation expense, weighted average period of recognition						4 years 8 months 12 days
Unrecognized compensation expense related to restricted shares				$ 151,000		$ 151,000
Employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted						1,022,500
Weighted average grant date fair value						$ 6.98
Percentage of estimated forfeiture rate						5.00%
Unrecognized compensation expense related to options				5,100,000		$ 5,100,000
Unrecognized compensation expense, weighted average period of recognition						4 years
Non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Percentage of estimated forfeiture rate						5.00%
Unrecognized compensation expense related to options				400,000		$ 400,000
Unrecognized compensation expense, weighted average period of recognition						4 years
Presbia Holdings [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted						0
Options granted						0
Options outstanding	4,700,000							4,835,000
Exercises period	3,785,000					3,860,000
Exercise price	$ 0.08					$ 0.08
Options cancelled	956,250					975,000
Options forfeited/cancelled, weighted average exercise price per share	$ 0.24					$ 0.24
Share-based compensation expense				$ 21,000
Share based compensation vesting periods unvested stock options				665,000		665,000
Unrecognized stock-based compensation expense				$ 0		$ 0
Presbia Holdings [Member] | Restricted shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted						0
Restricted shares outstanding	1,400,000			400,000		400,000			1,000,000
Weighted average grant date fair value	$ 0.30
Vesting period restricted shares value	$ 104,000
Vesting weighted average grant date fair value	$ 0.26

Share Based Awards - Schedule o

Share Based Awards - Schedule of Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	May. 13, 2015	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of shares, Granted		1,089,000
Number of shares, Forfeited/cancelled		(9,750)
Number of shares, Ending Balance		1,079,250
Number of shares, Vested and expected to vest		972,000
Number of shares, Exercisable		92,000
Weighted average exercise price per share, Granted		$ 9.80
Weighted average exercise price per share, Forfeited/cancelled		8.63
Weighted average exercise price per share, Ending Balance		9.81
Weighted average exercise price per share, Vested and expected to vest		9.80
Weighted average exercise price per shares, Exercisable		$ 9.97
Presbia Holdings [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of shares, Beginning balance		4,835,000
Number of shares, Granted		0
Number of shares, Exercised	(3,785,000)	(3,860,000)
Number of shares, Forfeited/cancelled	(956,250)	(975,000)
Number of shares, Ending Balance	4,700,000
Weighted average exercise price per share, Beginning Balance		$ 0.11
Weighted average exercise price per share, Exercised	$ 0.08	0.08
Weighted average exercise price per share, Forfeited/cancelled	$ 0.24	$ 0.24
Aggregate intrinsic value, Exercisable		$ 656

Share Based Awards - Share-Base

Share Based Awards - Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 551	$ 85	$ 1,403	$ 194
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	81	52	107	135
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	424	28	1,220	49
Sales and marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 46	$ 5	$ 76	$ 10

Share Based Awards - Schedule36

Share Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) - Jun. 30, 2015	Total	Total
Employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected life	6 years 6 months
Expected volatility	84.50%
Expected volatility minimum		76.80%
Expected volatility maximum		84.50%
Expected dividends	0.00%	0.00%
Risk-free rate	1.80%
Risk-free rate minimum		1.30%
Risk-free rate maximum		1.80%
Employee options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected life		5 years 6 months
Employee options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected life		6 years 6 months
Non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected life	9 years 10 months 24 days	9 years 10 months 24 days
Expected volatility	78.80%	78.80%
Expected dividends	0.00%	0.00%
Risk-free rate	2.40%
Risk-free rate minimum		1.90%
Risk-free rate maximum		2.40%

Share Based Awards - Schedule37

Share Based Awards - Schedule of Restricted Share Activity (Detail) - Restricted shares [Member] - $ / shares	Mar. 16, 2015	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of shares, Granted		18,540
Number of shares, Ending Balance		18,540
Number of shares, Vested and expected to vest		18,540
Weighted average exercise price per share, Granted	$ 8.63	$ 8.63
Weighted average exercise price per share, Ending Balance		8.63
Weighted average exercise price per share, Vested and expected to vest		$ 8.63

Related Party Transactions - Sc

Related Party Transactions - Schedule of Amounts Due to Related Parties (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Payable to related parties—current:
Total	$ 59	$ 12
Payable due to the Parent—noncurrent:
Total		417
Management services [Member]
Payable to related parties—current:
Management services provided by related parties	$ 59	12
The Parent [Member]
Payable due to the Parent—noncurrent:
Principal amounts due to the Parent		$ 417

Concentration of Credit Risk -

Concentration of Credit Risk - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Risks And Uncertainties [Abstract]
Cash	$ 29,806	$ 138	$ 363	$ 584

Operating Segments and Geogra40

Operating Segments and Geographic Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2015Segment
Segment Reporting [Abstract]
Number of reportable segments	1

Operating Segments and Geogra41

Operating Segments and Geographic Information - Schedule of Revenues Generated from External Customers and Long-lived Assets by Area (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 42	$ 61	$ 115	$ 87
Long Lived Assets	803		803		$ 747
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	25	60	60	81
Korea [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues			36
Japan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues				5
Netherlands [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	11		11
Australia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1		1
Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	5	$ 1	7	$ 1
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	771		771		716
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	$ 32		$ 32		$ 31

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - shares	Aug. 03, 2015	Jun. 30, 2015
Subsequent Event [Line Items]
Liquidation plan		On August 3, 2015, Presbia Holdings, as part of the liquidation plan approved on May 13, 2015 by its shareholders, completed the distribution to its shareholders of 9,666,667 ordinary shares of Presbia PLC and 39,994 of deferred ordinary shares, representing all of its holdings in Presbia PLC.
Liquidation date		May 13, 2015
Subsequent Event [Member] | Presbia Holdings [Member] | Ordinary Shares [Member]
Subsequent Event [Line Items]
Shares outstanding	9,666,667
Subsequent Event [Member] | Presbia Holdings [Member] | Deferred Ordinary Shares [Member]
Subsequent Event [Line Items]
Shares outstanding	39,994